ADTX Company Profile and Key Details

Q: Who are the executives of ADTX?

Dr. Dolly B. Tyan Ph.D.Senior Vice President of Clinical Devel. TransplantationMr. Amro A. AlbannaCo-Founder, Chairman & Chief Executive OfficerMs. Corinne D. Pankovcin CPA, CPA, M.B.A.PresMr. Matthew M. ShatzkesChief Legal Officer & Gen. CounselMs. Rowena AlbannaChief Operating OfficerMr. Thomas J. Farley CPAChief Financial OfficerMs. Maureen ConnollyChief Content & Engagement OfficerMs. Corinne D. Pankovcin C.P.A., CPA, M.B.A.Chief Commercialization OfficerMr. Ge Chen M.D., M.S.Senior Vice President of Preclinical Research & DiscoveryDr. Shahrokh Shabahang D.D.S., M.S., Ph.D.Co-Founder, Chief Innovation Officer, Sec. & DirectorMr. Matthew M. Shatzkes Esq.Chief Legal Officer, Gen. Counsel & Corporation Sec.

NASDAQ : ADTX

Aditxt

$0.35

-0.0873-20.10%

At Close 4:00 PM

$0.33

0.3470-5.94%

Pre-Market 08:30 PM

66.54

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Aditxt, Inc. (ADTX) stock declined over -20.10%, trading at $0.35 on NASDAQ, down from the previous close of $0.43. The stock opened at $0.39, fluctuating between $0.32 and $0.40 in the recent session.

Stock Snapshot

0.4343

Prev. Close

933

Market Cap

0.3201

Day Low

N/A

P/E Ratio

-9230.64

EPS (TTM)

-14.1

Cash Flow per Share

0.39

Open

2.69K

Number of Shares

0.4009

Day High

100%

Free Float in %

12.17

Book Value

22.16M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 20, 2026	0.40	0.40	0.32	0.35	22.18M
Apr 17, 2026	0.45	0.45	0.42	0.43	280.34K
Apr 16, 2026	0.42	0.45	0.41	0.43	566.46K
Apr 14, 2026	0.42	0.53	0.40	0.42	2.78M
Apr 13, 2026	0.47	0.48	0.39	0.47	953.03K
Apr 10, 2026	0.52	0.54	0.50	0.50	420.64K
Apr 09, 2026	0.51	0.54	0.50	0.53	569.98K
Apr 08, 2026	0.52	0.54	0.50	0.52	759.43K
Apr 07, 2026	0.52	0.53	0.50	0.52	796.06K
Apr 06, 2026	0.79	0.83	0.53	0.60	17.13M
Apr 02, 2026	0.93	1.14	0.76	0.79	797.68K
Apr 01, 2026	0.95	0.97	0.82	0.90	272.86K
Mar 31, 2026	0.80	1.02	0.80	0.98	695.9K
Mar 30, 2026	0.84	0.84	0.76	0.79	147.27K
Mar 27, 2026	0.90	0.90	0.80	0.81	127.02K
Mar 25, 2026	1.03	1.03	0.88	0.91	68.86K
Mar 24, 2026	1.06	1.10	0.93	0.97	141.61K
Mar 23, 2026	1.29	1.32	1.03	1.08	204.59K
Mar 20, 2026	1.24	1.30	1.21	1.30	83.48K
Mar 19, 2026	1.38	1.42	1.21	1.25	141.64K

Contact Details

Mountain View, VA 23219

United States

https://www.aditxt.com 909 488 0844

About Company

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Stock Peers

ARGX

-14.59-1.72%

argenx SE$834.45 REGN

-1.16-0.15%

Regeneron Pharmaceuticals, Inc.$749.41 UTHR

-14.94-2.54%

United Therapeutics Corporation$573.44 MDGL

-4.91-0.92%

Madrigal Pharmaceuticals, Inc.$527.11 VRTX

-2.02-0.46%

Vertex Pharmaceuticals Incorporated$439.18 PRAX

0.07+0.02%

Praxis Precision Medicines, Inc.$342.57 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.28+0.41%

Alnylam Pharmaceuticals, Inc.$310.94 KRYS

2.29+0.84%

Krystal Biotech, Inc.$276.50 ASND

0.9+0.37%

Ascendis Pharma A/S$245.38

Company Overview

Aditxt, Inc. (NASDAQ:ADTX) closed at $0.35 USD, losing -$0.09 (-20.10%) from the previous close of $0.43. The stock is currently mid-range between its 52-week high and low $0.32 and $2.50 thousand. With a market capitalization of about $933.00, Aditxt, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.40). Key stats such as the average daily volume over the past year has been around 884.95 thousand shares, trading with heavier-than-usual volume. Headquartered in Mountain View, VA, Aditxt, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Amro A. Albanna, the company employs approximately 26 people and listed since June 30, 2020. Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.

Technical Performance

ADTX has shown mixed momentum, gaining 44.82% over the past week and -96.8% over the past quarter, though year-to-date performance is up 41.4%. Short-term trend indicators are bullishly aligned (SMA20 -24.81%, SMA50 -45.72%, SMA200 -99.36%). The stock’s 14-day RSI is 26.98 (weak momentum), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.98% below its high and over -4.12% above its low. Average 10-day trading volume of 5.35 million shares is significantly above the 3-month average of 954.99 thousand, indicating heightened recent market interest.

Valuation Metrics

Aditxt, Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.02 suggesting the stock is closer to book value. The P/FCF stands at -0.0, also below market averages.

Dividend & Fair Value

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Earnings & Analyst Outlook

Aditxt, Inc. generated EPS of -$6,410.45 over the past year. Five-year average earnings growth is 83.15%. Aditxt, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 24, 2025, missed forecasts by -99.62%. The prior quarter beat by 1.34%. Over the last six quarters, Apple has recorded several small beats. These include 114.82% in April 02, 2024.

Shareholding & Insider Activity

Aditxt, Inc. has 517.86 thousand shares outstanding. The public float is 824.84 thousand shares, elevated short interest at 8.54% of float. This equals 44.23 thousand shares. The short ratio is 0.45 days. Institutional investors hold 0.02% of the float. Insiders own 0.0%. Shabahang Shahrokh holds 1.02 million shares, Albanna Rowena has 748.72 thousand shares and BNP PARIBAS SECURITIES CORP has 22.34 thousand shares. Over the past six months, insider transactions show net selling. They sold 2.00 shares across 2 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Aditxt generated $645.18K in revenue, or $2.13 per share. Gross margin was -101.41%, operating margin -4039.58%, and net profit margin -5018.92%. Returns are negative, with ROA at -72.64% and ROE at -201.67%.
On valuation metrics, Aditxt trades at a P/E of -0.00, P/S of 0.00 and P/B of 0.02. Liquidity is tight, with a current ratio of 0.31 and quick ratio of -0.16. Operationally, the company’s inventory turnover is 0.51 and cash conversion cycle is -195.34 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 535.95, supported by a cash flow-to-debt ratio of -0.01.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Aditxt posted revenue of $645.18K, down slightly from $933.72K in the prior quarter. Gross profit was - $654.24K (margin -101.41%). Operating income was - $26.06M (margin -4039.6%). Net income was- $32.38M (EPS - $108.15).
The company ended the quarter with $97.10K in cash and short-term investments, a total debt of $18.07M, and net debt of $17.97M. Total assets were $44.58M, with equity of $16.05M. Financials further reflected weakness, with operating cash flow of - $18.58M, free cash flow of - $18.59M, and capital expenditures of - $14.41K.

Price Forecast & Outlook

Our AI price prediction model suggests that Aditxt, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -100.0%, with price expected at $0.00 by May 04, 2026, within a range of $0.00 to $0.00 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by July 17, 2026, with a range of $0.00 to $88.44 thousand. 1-Year Outlook: Projected gain of 103657.93%, with price at $360.04 by April 20, 2027, within a range of $0.00 to $7.24 million.

Key Takeaways

Aditxt, Inc. (NASDAQ:ADTX) shares are up 41.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aditxt, Inc. trading at a premium to the broader market with a P/E of -0.0. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $32.50, suggesting 9265.99% upside. Our AI forecast model points to short-term weakness (-100.0% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term gain (103657.93% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Aditxt, Inc. (ADTX) stock price?

Aditxt, Inc. (NASDAQ: ADTX) stock price is $0.35 in the last trading session. During the trading session, ADTX stock reached the peak price of $0.40 while $0.32 was the lowest point it dropped to. The percentage change in ADTX stock occurred in the recent session was -20.1% while the dollar amount for the price change in ADTX stock was - $0.09.

ADTX's industry and sector of operation?

The NASDAQ listed ADTX is part of Biotechnology industry that operates in the broader Healthcare sector. Aditxt, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ADTX?

Dr. Dolly B. Tyan Ph.D.
Senior Vice President of Clinical Devel. Transplantation
Mr. Amro A. Albanna
Co-Founder, Chairman & Chief Executive Officer
Ms. Corinne D. Pankovcin CPA, CPA, M.B.A.
Pres
Mr. Matthew M. Shatzkes
Chief Legal Officer & Gen. Counsel
Ms. Rowena Albanna
Chief Operating Officer
Mr. Thomas J. Farley CPA
Chief Financial Officer
Ms. Maureen Connolly
Chief Content & Engagement Officer
Ms. Corinne D. Pankovcin C.P.A., CPA, M.B.A.
Chief Commercialization Officer
Mr. Ge Chen M.D., M.S.
Senior Vice President of Preclinical Research & Discovery
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D.
Co-Founder, Chief Innovation Officer, Sec. & Director
Mr. Matthew M. Shatzkes Esq.
Chief Legal Officer, Gen. Counsel & Corporation Sec.

How ADTX did perform over past 52-week?

ADTX's closing price is 8.4% higher than its 52-week low of $0.32 where as its distance from 52-week high of $2,495.04 is -99.99%.

How many employees does ADTX have?

Number of ADTX employees currently stands at 26.

Link for ADTX official website?

Official Website of ADTX is: https://www.aditxt.com

How do I contact ADTX?

ADTX could be contacted at phone 909 488 0844 and can also be accessed through its website. ADTX operates from 737 North Fifth Street, Mountain View, VA 23219, United States.

How many shares of ADTX are traded daily?

ADTX stock volume for the day was 22.16M shares. The average number of ADTX shares traded daily for last 3 months was 884.95K.

What is the market cap of ADTX currently?

The market value of ADTX currently stands at $933.00 with its latest stock price at $0.35 and 2.69K of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	26
Beta	1.51
Sales or Revenue	$645.18K
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ADTX Company Profile and Key Details

Aditxt

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Dividend & Fair Value

Technical Performance

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights